Camizestrant

• Description:

  Camizestrant (AZD-9833) is a potent and orally active estrogen receptor (ER) antagonist. Camizestrant is used for the study of ER+ HER2-advanced breast cancer[1].

• Product Name Alternative:

  AZD-9833

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Estrogen Receptor/ERR

• Type:

  Reference compound

• Related Pathways:

  Vitamin D Related/Nuclear Receptor

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/estrogen-receptor-antagonist-2.html

• Purity:

  99.32

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  FC(F)(F)CN1[C@H](C2=CC=C(NC3CN(CCCF)C3)C=N2)C4=C(C5=C(NN=C5)C=C4)C[C@H]1C

• Molecular Formula:

  C24H28F4N6

• Molecular Weight:

  476.51

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Bernard Christophe Barlaam, etal. Chemical compounds. Patent US20180111931.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 3

• CAS Number:

  [2222844-89-3]